Definitive Contract N6600121C4010

Award Date 2/1/21
Potential Completion Date 2/1/26
Potential Value $16M
Ultimate Awardee
Leidos Holdings, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Herndon, VA 20190, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
7
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Advanced Research Projects Agency (DARPA) to Leidos, Inc. for a research project. The contract is a definitive, cost-plus-fixed-fee contract with a ceiling value of $1,485,940.00 and a completion date of February 18, 2020. The contract is not set aside for a specific business size. Leidos, Inc., a global technology and engineering solutions provider, is the prime contractor. The contract supports DARPA's research initiatives, which may include...
This is a $23,436,678.00 cost-plus-fixed-fee definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Leidos, Inc. for a DARPA research project. The contract has no set-aside designation. The work will be performed in Herndon, Virginia and has an ultimate completion date of October 22, 2028. Leidos, Inc. is a large business prime contractor that is a subsidiary of Leidos Holdings, Inc. The contract demonstrates Leidos' capabilities in providing research and...
This is a $5,565,210.00 federal research and development contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Leidos Inc. The contract is a definitive contract with a cost-no-fee pricing type and was awarded on November 2, 2017, with a completion date of August 31, 2019. The contract did not have a set-aside designation. As the prime contractor, Leidos has leveraged its expertise in areas like systems integration, cybersecurity, and advanced research and development to...
This is a Cost Plus Fixed Fee definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Leidos, Inc. for a DARPA research project. The contract has a ceiling value of $7,585,670.20 and a completion date of June 30, 2025. Leidos, a global technology and engineering solutions provider, will perform the work at its facility in Herndon, Virginia. The contract does not have a set-aside designation, indicating Leidos competed as a large business prime contractor. Leidos...
This is a definitive cost-plus-fixed-fee contract valued at $10,846,804.00 awarded by the Defense Advanced Research Projects Agency (DARPA) to Leidos, Inc. for a DARPA research project. The contract has no set-aside designation, indicating Leidos' competitiveness as a large business prime contractor. Leidos has subcontracted with the University of Hawaii, J. Craig Venter Institute, Signature Science LLC, and Monell Chemical Senses Center to provide specialized research services and expertise...
This is a cost-plus-fixed-fee contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Leidos, Inc. for a DARPA research project. The contract has a ceiling value of $14,233,874.98 and a period of performance through December 31, 2020. No set-aside designation was used. As the prime contractor, Leidos has subcontracted work to several companies, including Mercury Systems, Inc., Jariet Technologies, Inc., Colorado Engineering Inc., and Alliant Techsystems Operations LLC. The...
This is a $490,125.00 cost-plus-fixed-fee definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Leidos, Inc. for the Leidos Protected Asset Survivability Study (PASS) project. The contract has no set-aside designation, indicating Leidos competed as a large business prime contractor. The PASS project supports DARPA's mission to develop advanced technologies for national security applications. Leidos will leverage its expertise in areas such as space...
The Defense Advanced Research Projects Agency awarded a cost-plus-fixed-fee contract valued at approximately $10.4 million to Leidos Inc., operating as Saic, to support coronavirus COVID-19 research efforts. The prime contractor will conduct work at its Herndon, Virginia location from June 2020 through September 2025. Leidos named Quasar Federal Systems and Clinical Practices of the University of Pennsylvania as major subcontractors to assist with procurements in support of the statement of work...
This is a $18,018,800.00 cost-plus-fixed-fee definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Leidos, Inc. The contract supports the "Maritime Materials Technologies (M2T)" program, which seeks expertise in biomimetic chemistry and lifecycle biology of r-selected marine organisms. No set-aside designation was used for this award. Leidos, a global technology and engineering solutions provider, will perform the contract work at its facility in...
This is a $574,487.00 cost-plus-fixed-fee contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Leidos, Inc. for "Repository Based Binary Verification" work. The contract has a ceiling value of $574,487.00 and a completion date of February 28, 2018. It is a definitive contract and does not have a set-aside designation. Leidos, Inc. is the prime contractor, and its parent company is Leidos Holdings, Inc. The contract supports DARPA's research and development...

The U.S. Naval Information Warfare Systems Command (NAVWAR) awarded Leidos, Inc. a 5-year, $15,820,007.00 cost-plus-fixed-fee research and development contract in support of a DARPA program. The contract, which has no set-aside designation, aims to develop a Personalized Protective Biosystem (PPB) to provide lightweight, unburdened protection against chemical and biological threats. The PPB program will integrate materials that prevent agent exposure with secondary tissue-level defenses for the skin, eyes, and airways. Leidos, as the prime contractor, will advance the system design through a five-phase R&D effort, with effectiveness evaluated through milestone testing of prototypes and ensembles. The goal is regulatory approval for human use by the end of Phase III.

Generated 10/17/24, 9:48 AM